Retatrutide vs tirzepatide: what the published research shows

Retatrutide vs tirzepatide. Both are multi-agonist compounds in the incretin-receptor family, and both are frequently searched together — but they are not the same kind of thing. Tirzepatide is an approved dual agonist; retatrutide is an investigational compound studied in published research as a triple agonist. This guide compares their receptor mechanism from the published literature. It is written cite-don’t-endorse and makes no substitute claim: Elite AU Peptides supplies research-grade retatrutide for laboratory use only and does not supply tirzepatide (an approved medicine).

The one-line difference: two receptors versus three

Tirzepatide is an approved dual agonist of the GLP-1 and GIP receptors. Retatrutide is studied as a triple agonist that adds glucagon-receptor activity on the same peptide backbone. That third receptor — glucagon — is the defining mechanistic distinction between the two in the research literature. Everything else in the comparison follows from it.

What the published research reports

The receptor pharmacology of retatrutide as a balanced triple agonist was reported by Coskun and colleagues (Cell Metabolism, 2022), who characterised its balanced glucagon- and GLP-1-receptor activity alongside greater GIP-receptor activity; its first-in-human pharmacokinetics were reported by Urva and colleagues (The Lancet, 2022). Tirzepatide’s dual-agonist profile is documented across the SURPASS clinical-trial programme (for example, Frías and colleagues, New England Journal of Medicine, 2021). These are cited as published research findings only — retatrutide extends the multi-agonist concept beyond tirzepatide by adding glucagon-receptor activity, which is precisely why the two are compared in receptor-pharmacology research.

Approval status — the distinction that matters most

Tirzepatide is an approved medicine. Retatrutide is not — it is an investigational compound in published research. Elite AU Peptides supplies research-grade retatrutide strictly for in-vitro and laboratory research use only; we do not supply tirzepatide, which is an approved prescription medicine outside our catalogue. Neither is offered here for human use, and nothing in this comparison should be read as a recommendation to use one in place of the other. For the wider context, see the GLP-1 research peptides pillar guide, and for the single-receptor comparison, the semaglutide vs retatrutide guide.

Identity, purity and the COA moat

Every batch of retatrutide supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the retatrutide product page and in the lab-reports library — a real batch number, the measured percentage, and an independently verifiable Janoshik report. Retatrutide is stocked in 10mg, 15mg, 20mg and 30mg lyophilised vials; nothing is listed without a certificate on file.

Compliance and research-use framing

This guide is a research-reference comparison of receptor mechanism drawn from published literature. Elite AU Peptides makes no medical, therapeutic, weight-loss, or body-composition claim about retatrutide, makes no claim that it is a substitute for or equivalent to any approved medicine, and does not supply tirzepatide. Research-grade retatrutide is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption. Clinical questions about an approved medicine belong with a qualified healthcare professional.